ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
6.04
-0.27 (-4.28%)
Oct 6, 2026, 4:00 PM EDT - Market closed
ENDRA Life Sciences Earnings Call Transcripts
Fiscal Year 2024
-
Q2 2024 saw a $7.3M capital raise, 26% cut in operating expenses, and a strategic shift toward primary care and endocrinology for the TAEUS liver device. FDA submission is targeted for mid-2025, with a strengthened management team and expanded patent portfolio.